|Bid||1.80 x 4000|
|Ask||1.92 x 1100|
|Day's Range||1.8500 - 1.9200|
|52 Week Range||1.7800 - 4.5500|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.89|
SAN DIEGO and TORONTO, Feb. 19, 2019 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SAN DIEGO and TORONTO, Jan. 02, 2019 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
SAN DIEGO and TORONTO, Dec. 12, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL) breakfast featuring a presentation.
PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the.
SAN DIEGO and TORONTO, Dec. 03, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The.
“We are pleased to announce the successful re-initiation of patient dosing in our clinical trial with APTO-253, our first-in-class inhibitor of the MYC oncogene that has the potential to benefit a large patient population across various therapeutic areas, and we look forward to providing updates moving forward,” commented William G. Rice, Ph.D., Chairman, President and CEO. “As the clinical protocol requires only one patient at each of the two lowest dose levels, we have and will continue to carefully select patients for those first two dose levels.
On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 16 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.38. A year ago, they were trading at ...
The Mississauga, Ontario-based company said it had a loss of 30 cents per share. The company's shares closed at $2.75. A year ago, they were trading at $1.69. _____ This story was generated by Automated ...
In this article, I’m going to take a look at Aptose Biosciences Inc’s (TSE:APS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...